Childhood Disintegration Disorder
- Author: Bettina E Bernstein, DO; Chief Editor: Caroly Pataki, MD more...
Background
Childhood disintegrative (or disintegration) disorder, also known as Heller syndrome, is characterized by a loss of previously acquired language and social skills and results in a persistent delay in these areas. For example, a child previously able to speak in 2- or 3-word phrases gradually or abruptly loses the ability to communicate using words or can use only fragments.
Social and emotional development also regress, resulting in an impaired ability to relate with others. For example, a child who was previously able to accept reassurance from his or her parent (eg, a hug) loses the ability to be consoled and may even withdraw from human (tactile) contact.
Childhood disintegrative disorder occurs in about 2 per 100,000 children and thus is much rarer than either autistic disorder, which affects 20 per 10,000 children, or pervasive developmental disorder, not otherwise specified (PDD-NOS), which occurs in 30 per 10,000 children.[1] Childhood disintegrative disorder generally manifests by the fourth year of life, after a period of at least 2 years of normal development.
Overall, the social, communicative, and behavioral features of childhood disintegrative disorder resemble those of autistic disorder. Affected children have distinct qualitative impairments in social interaction and communication. In addition, restricted, repetitive, or stereotyped patterns of behavior, interests, and activities occur. Previously acquired motor skills are lost (eg, a child who was toilet-trained begins to soil during the day and night, or a child who was able to pedal a tricycle or draw shapes can no longer do so).
Additional symptoms may include the onset of difficulty in the transition to waking from sleep. Social interactions become compromised (as manifested by aggressiveness, tantrums, or withdrawal from peers), as does motor function, resulting in poor coordination and possible awkwardness of gait.[2]
Family home movies can be very helpful in early identification of autistic spectrum disorders (ASDs), including childhood disintegrative disorder.[3]
Illustrative case
A 3-year-old boy is referred for evaluation because his behavior has recently gotten him “expelled” from daycare. He screams, throws tantrums, and no longer accepts hugs from his daycare teacher, with whom he was previously familiar. He has lately become destructive to his toys and does not use them to interact with his peers. His parents report that he was doing “okay” up until the past 3 months. They do not report that he had had any language delays.
Pathophysiology
It was long held, erroneously, that “refrigerator mothers” (a term coined on the basis of the presumed emotional frigidity of such mothers toward their children) caused ASDs in their children. This flawed theory has caused unnecessary psychological pain in countless families. However, current research has yet to reveal a clear-cut pathophysiology for childhood disintegrative disorder, and there remains considerable debate within the developmental disabilities field regarding the long-term outcomes of children with this condition.
Some researchers hypothesize that genetic predispositions combined with environmental stressors (eg, virus exposure or birth trauma) result in brain deposition of amyloid and disruption of synaptic transmissions, possibly involving interleukin-1 (IL-1) or beta-endorphins. Provision of enriched environmental experiences during critical periods of development may restore brain plasticity and thus mitigate genetic predispositions. However, earlier disruption of psychosocial development can result in even more severe developmental consequences.
Several researchers have theorized that altered or inappropriate immune responses, potentially involving abnormal B-cell activation and neuronal function, may play a role in the pathophysiology. In this regard, some studies have found that lithium and hyperbaric oxygen[4] reduce oxidative stress and may increase blood flow to the brain, lending some support to the idea that a possible endophenotype leads to oxidative stress and neuronal injury.[5, 6, 7, 1]
Autoantibodies to myelin basic protein (MBP) in children with childhood disintegrative disorder appear to differ from those in children with nonregressive forms of autism; however, this finding has not yet been shown to correlate with disease severity or prognosis.[5]
No gene has yet been isolated as the cause of childhood disintegrative disorder; however, a gene that codes for elongator protein complex 4 (ELP4) has been identified on human chromosome 11 and appears to be associated with centrotemporal spikes (CTS), the electroencephalographic (EEG) feature typical of rolandic epilepsy (RE).
ELP4 is one component of the elongator complex, a group of 6 genes that function in transcription and modification of transfer RNA (including regulating the actin cytoskeleton, cell motility, and migration) and that seem to play a critical role in influencing genes important to neuronal migration, axon growth, motility of growth cones, and related activities.[8]
ELP4 may also play a critical role in the transcription and modification of transfer RNA. Interference with necessary migration, synaptogenesis, and division in the central nervous system (CNS) before adolescence may result from disruption of transcriptional regulatory and translational modification roles and may render dendrites unable to make the proper neuronal connections.[9]
ASDs, including PDD, are generally associated with an increased incidence of seizures. Other idiopathic focal epilepsies occur during sleep. In addition, other epilepsy syndromes are associated with impaired frontal lobe and language function, potentially leading to continuous epileptiform discharges during sleep.[10]
Etiology
No single causative factor for childhood disintegrative disorder has been identified. Research suggests that a combination of genetic susceptibility, including possibly abnormal autoimmunity, and prenatal (or environmental) stress may explain the pathophysiologic findings of higher-than-expected brain deposition of amyloid and disruption of synaptic transmission.
As the child experiences developmental departure from normality, the diminished preferential attention to the eyes of others has cascading detrimental effects, decreasing further socialization. The child’s attention focuses on aspects (eg, point sounds, lights, and lip motions), leading to further impairment of appropriate social interaction (mediated by eye contact and facial expression).[17]
Environmental risk factors for childhood disintegrative disorder include the following:
- Viral exposure (usually intrauterine transmission) -Toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes simplex (TORCH)
- Birth trauma
- Toxin exposure
- Teratogenicity – Research directions include the possible association of ophthalmologic malformations with ASDs resulting from the teratogenicity of thalidomide and misoprostol[18, 19]
Genetic factors include the following:
- Possible susceptibility to chromosomal breakage or disruption
- Family history of autism or Asperger disorder
- Family history of RE, with or without CTS – RE commonly affects prepubescent children aged 3-12 years, occurring in about 1 per 500 children (60% of whom are boys); seizures in RE typically begin as groaning noises (in the larynx) that interfere with speech and then may present as sensorimotor activity; seizures in benign RE (BRE) occur at night and during sleep, possibly because sleep is associated with a lowered seizure threshold[20, 21]
- CTS are also associated with attention deficit/hyperactivity disorder (ADHD), speech disorders, and developmental coordination disorder; in many cases, CTS due to RE are missed because the child’s history of falls can be mistakenly attributed to poor coordination[21]
Disorders associated with childhood disintegrative disorder include the following:
Epidemiology
In the United States, childhood disintegrative disorder is very rare (affecting 2 per 100,000 children), much rarer than autistic disorder (which affects 20 per 10,000 children).[1] No current studies are large enough to determine the international frequency of childhood disintegrative disorder.
Childhood disintegrative disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), occurs only after a period of at least 2 years of normal development, when the child is younger than 10 years.[13, 1] Onset generally occurs in children aged 3-4 years and may be insidious or abrupt. The average age at diagnosis is 3.9 years, comparable to that of autistic disorder (average age, 3.1 years; range, 4.1-5.5 years in some studies).[1]
Childhood disintegrative disorder is slightly more common in males than in females.[1] No studies have shown childhood disintegrative disorder to be any more or less common in any particular race or culture.
Prognosis
The prognosis of childhood disintegrative disorder has been considered guarded; because the disorder is so rare, more data are needed.[2] Children with moderate-to-severe mental retardation or lack of communicative language have a worse prognosis than those with usual intelligence and communicative language.[2, 26] The disorder is lifelong, and the social, communicative, and behavioral difficulties tend to impair function throughout life.[2, 46]
No mortality or morbidity is directly attributable to childhood disintegrative disorder. Indirectly, a comorbid medical condition, such as a neurodegenerative disorder, may increase the risk of mortality and morbidity. The clinician should be alert to the possibility of Landau-Kleffner syndrome (LKS).[11, 12]
LKS is a rare condition of unknown etiology that is more common in boys. LKS generally presents with more severe language impairment and later than childhood disintegrative disorder; LKS has a mean age of onset of 5.5 years. Excluding this syndrome is important because it is generally associated with seizure disorder and may respond to treatment with anticonvulsants such as valproic acid or steroids.[11, 12]
The risk of seizures increases with age and peaks at adolescence. Concomitant administration of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and low-dose high-potency neuroleptics such as haloperidol tends to lower the seizure threshold (as does alcohol), which may increase the likelihood of seizures.[34]
Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. Jun 2009;65(6):591-8. [Medline].
Volkmar FR, State M, Klin A. Autism and autism spectrum disorders: diagnostic issues for the coming decade. J Child Psychol Psychiatry. Jan 2009;50(1-2):108-15. [Medline].
Palomo R, Thompson M, Colombi C, Cook I, Goldring S, Young GS, et al. A case study of childhood disintegrative disorder using systematic analysis of family home movies. J Autism Dev Disord. Nov 2008;38(10):1853-8. [Medline].
Rossignol DA, Rossignol LW, Smith S, Schneider C, Logerquist S, Usman A, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. Mar 13 2009;9:21. [Medline].
Libbey JE, Coon HH, Kirkman NJ, Sweeten TL, Miller JN, Stevenson EK, et al. Are there enhanced MBP autoantibodies in autism?. J Autism Dev Disord. Feb 2008;38(2):324-32. [Medline].
Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. Apr 2003;160(4):636-45. [Medline].
Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. Aug 2008;29(4):293-302. [Medline].
Strug LJ, Clarke T, Chiang T, Chien M, Baskurt Z, Li W, et al. Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4). Eur J Hum Genet. Sep 2009;17(9):1171-81. [Medline].
Ortega-Hernandez OD, Kivity S, Shoenfeld Y. Olfaction, psychiatric disorders and autoimmunity: is there a common genetic association?. Autoimmunity. Jan 2009;42(1):80-8. [Medline].
Lillywhite LM, Saling MM, Harvey AS, Abbott DF, Archer JS, Vears DF, et al. Neuropsychological and functional MRI studies provide converging evidence of anterior language dysfunction in BECTS. Epilepsia. Oct 2009;50(10):2276-84. [Medline].
Mordekar SR, Prendergast M, Chattopadhyay AK, Baxter PS. Corticosteroid treatment of behaviour, language and motor regression in childhood disintegrative disorder. Eur J Paediatr Neurol. Jul 13 2008;[Medline].
Russo M, Perry R, Kolodny E, Gillberg C. Heller syndrome in a pre-school boy. Proposed medical evaluation and hypothesized pathogenesis. Eur Child Adolesc Psychiatry. Sep 1996;5(3):172-7. [Medline].
American Psychiatric Association. Childhood Disintegrative Disorder 299.10. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994:73-5.
Kurita H, Koyama T, Osada H. Comparison of childhood disintegrative disorder and disintegrative psychosis not diagnosed as childhood disintegrative disorder. Psychiatry Clin Neurosci. Apr 2005;59(2):200-5. [Medline].
Young EC, Diehl JJ, Morris D, et al. The use of two language tests to identify pragmatic language problems in children with autism spectrum disorders. Lang Speech Hear Serv Sch. Jan 2005;36(1):62-72. [Medline].
Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs. May 2009;10(5):463-73. [Medline].
Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. Oct 2008;17(4):787-801, viii-ix. [Medline].
Miller MT, Ventura L, Strömland K. Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol. Aug 2009;85(8):667-76. [Medline].
Miller MT, Strömland K, Ventura L, Johansson M, Bandim JM, Gillberg C. Autism with ophthalmologic malformations: the plot thickens. Trans Am Ophthalmol Soc. 2004;102:107-20; discussion 120-1. [Medline].
Tedrus GM, Fonseca LC, Melo EM, Ximenes VL. Educational problems related to quantitative EEG changes in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. Aug 2009;15(4):486-90. [Medline].
Watemberg N, Leitner Y, Fattal-Valevski A, Kramer U. Epileptic negative myoclonus as the presenting seizure type in rolandic epilepsy. Pediatr Neurol. Jul 2009;41(1):59-64. [Medline].
Jyonouchi H, Geng L, Ruby A, et al. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. May 2005;146(5):605-10. [Medline].
Stigler KA, Posey DJ, McDougle CJ. Ramelteon for insomnia in two youths with autistic disorder. J Child Adolesc Psychopharmacol. Oct 2006;16(5):631-6. [Medline].
Cohen IL, Schmidt-Lackner S, Romanczyk R, Sudhalter V. The PDD Behavior Inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder. J Autism Dev Disord. Feb 2003;33(1):31-45. [Medline].
Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. Feb 2008;4(1):203-7. [Medline]. [Full Text].
Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. Oct 2008;17(4):739-52, vii-viii. [Medline].
Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69 Suppl 4:9-14. [Medline].
Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol. Jun 2009;19(3):265-74. [Medline].
King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. Jun 2009;66(6):583-90. [Medline].
Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry. 2008;16(2):97-112. [Medline].
Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. Oct 2008;17(4):803-20, ix. [Medline].
Duncan B, McDonough-Means S, Worden K, Schnyer R, Andrews J, Meaney FJ. Effectiveness of osteopathy in the cranial field and myofascial release versus acupuncture as complementary treatment for children with spastic cerebral palsy: a pilot study. J Am Osteopath Assoc. Oct 2008;108(10):559-70. [Medline].
Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. Oct 19 2005;CD003497. [Medline].
Akshoomoff N, Farid N, Courchesne E, Haas R. Abnormalities on the neurological examination and EEG in young children with pervasive developmental disorders. J Autism Dev Disord. May 2007;37(5):887-93. [Medline].
Murch S. Diet, immunity, and autistic spectrum disorders. J Pediatr. May 2005;146(5):582-4. [Medline].
Posey DJ, Aman MG, McCracken JT, Scahill L, Tierney E, Arnold LE, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. Feb 15 2007;61(4):538-44. [Medline].
Carlson T, Reynolds CA, Caplan R. Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. J Am Acad Child Adolesc Psychiatry. Mar 2007;46(3):356-61. [Medline].
Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. Nov 2004;19(6):351-3. [Medline].
Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol. Jul 2005;19(4):422-5. [Medline].
Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. Sep 2005;112(3):238-40; discussion 240. [Medline].
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. Jul 2006;114(1):1-7. [Medline].
Soares-Fernandes JP, Machado A, Ribeiro M, et al. Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy. Arch Neurol. Aug 2006;63(8):1202-3. [Medline].
Stewart JT. Treatment of valproate-induced hyperammonemia. J Am Geriatr Soc. Jun 2005;53(6):1080. [Medline].
[Guideline] Kagan-Kushnir T, Roberts SW, Snead OC 3rd. Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. J Child Neurol. Mar 2005;20(3):197-206. [Medline].
Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. May 2007;22(5):574-9. [Medline].
Agarwal V, Sitholey P, Mohan I. Childhood Disintegrative Disorder, an atypical presentation: a case report. J Autism Dev Disord. Dec 2005;35(6):873-4. [Medline].

